Zepbound Prior Authorization (2026): Criteria, Timelines, and What to Do While You Wait | PlexusDx
Zepbound prior authorization explained: BMI and comorbidity criteria, the OSA pathway, the CVS Caremark formulary change, ERISA timelines, and how to appeal a denial. Plus where the PlexusDx Tirzepatide Injection Protocol ($229–$309/mo) fits as a cash-pay bridge while a PA is pending or after a denial.
Zepbound for OSA: What It Means, Context, and Common Patient Questions
Zepbound (tirzepatide) was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. This article covers SURMOUNT-OSA trial outcomes, mechanism, safety, and the GLP-1 pathway genetics.
Zepbound for Sleep Apnea: 2024 FDA Indication and Evidence
Zepbound (tirzepatide) was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. This article covers SURMOUNT-OSA trial outcomes, mechanism, safety, and the GLP-1 pathway genetics.